In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi

Veterinary Microbiology

Volumn 160, Issue 1-2, 2012, Pages 207-213

  Giguère, Steeve ^a   Lee, Elise A ^b   Guldbech, Kristen M ^a   Berghaus, Londa J ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b ROSS UNIVERSITY SCHOOL OF VETERINARY MEDICINE   (Saint Kitts and Nevis)

Author keywords

Antimicrobial; Pneumonia; Postantibiotic effect; Rhodococcus equi; Synergism

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTIOFUR; CLARITHROMYCIN; DOXYCYCLINE; ENROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; RIFAMPICIN; VANCOMYCIN;

ARTICLE; ASSAY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DRUG ANTAGONISM; DRUG POTENTIATION; FOAL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; POSTANTIBIOTIC EFFECT; RHODOCOCCUS EQUI;

ACTINOMYCETALES INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; HORSE DISEASES; HORSES; HUMANS; RHODOCOCCUS EQUI;

RHODOCOCCUS EQUI;

EID: 84867020845     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2012.05.031     Document Type: Article

References (28)

1. Andes D., Anon J., Jacobs M.R., Craig W.A. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin. Lab Med. 2004, 24:477-502.
2. Carlson K., Kuskie K., Chaffin K., Libal M., Giguère S., Lawhon S., Cohen N. Antimicrobial activity of tulathromycin and 14 other antimicrobials against virulent Rhodococcus equi in vitro. Vet. Ther. 2010, 11:E1-E9.
3. Clinical Laboratory Standard Institute Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standards. CLSI document M31-A3 2008, Clinical and Laboratory Standard Institute, Wayne, PA.
4. Clinical Laboratory Standard Institute Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. CLSI document M100-S19 2009, Clinical and Laboratory Standard Institute, Waynes, PA.
5. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 2003, 17:479-501.
6. Craig W.A., Ebert S.C. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. Suppl. 1990, 74:63-70.
7. Craig W.A., Gudmundsson S. Postantibiotic effect. Antibiotics in Laboratory Medicine 1996, 296-328. Williams & Wilkins, Baltimore. V. Lorian (Ed.).
8. Cunha B.A., Domenico P., Cunha C.B. Pharmacodynamics of doxycycline. Clin. Microbiol. Infect. 2000, 6:270-273.
9. Ferrara A., Dos S.C., Cimbro M., Grassi G.G. Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens. Int. J. Antimicrob. Agents 1996, 7:181-186.
10. Giguère S., Cohen N.D., Keith C.M., Hines S.A., Hondalus M.K., Prescott J.F., Slovis N.M. Rhodococcus equi: clinical manifestations, virulence, and immunity. J. Vet Intern. Med. 2011, 25:1221-1230.
11. Giguère S., Cohen N.D., Keith C.M., Slovis N.M., Hondalus M.K., Hines S.A., Prescott J.F. Diagnosis, treatment control, and prevention of infections caused by Rhodococcus equi in foals. J. Vet Intern. Med. 2011, 25:1209-1220.
12. Giguère S., Jacks S., Roberts G.D., Hernandez J., Long M.T., Ellis C. Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia. J. Vet Intern. Med 2004, 18:568-573.
13. Giguère S., Lee E., Williams E., Cohen N.D., Chaffin M.K., Halbert N., Martens R.J., Franklin R.P., Clark C.C., Slovis N.M. Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of R. equi. J. Am. Vet. Med. Assoc. 2010, 237:74-81.
14. Harvey R.L., Sunstrum J.C. Rhodococcus equi infection in patients with and without human immunodeficiency virus infection. Rev. Infect. Dis. 1991, 13:139-145.
15. Hillidge C.J. Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia. Vet. Microbiol. 1987, 14:337-342.
16. Jacks S., Giguère S., Nguyen A. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin and 20 other antimicrobials. Antimicrob. Agents Chemother. 2003, 47:1742-1745.
17. Kedlaya I., Ing M.B., Wong S.S. Rhodococcus equi infections in immunocompetent hosts: case report and review. Clin. Infect. Dis. 2001, 32:E39-E46.
18. National Committee for Clinical Laboratory Standards Methods for determining bactericidal activity of antimicrobial agents; approved guidelines. NCCLS document M26-A 1999, Clinical and Laboratory Standard Institute, Waynes, PA.
19. Nordmann P., Kerestedjian J.J., Ronco E. Therapy of Rhodococcus equi disseminated infections in nude mice. Antimicrob. Agents Chemother. 1992, 36:1244-1248.
20. Nordmann P., Ronco E. In vitro antimicrobial susceptibility of Rhodococcus equi. J. Antimicrob. Chemother. 1992, 29:383-393.
21. Odenholt-Tornqvist I., Lowdin E., Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob. Agents Chemother. 1995, 39:221-226.
22. Pillai S.K., Moellering R.C., Eliopoulos G.M. Antimicrobial combinations. Antibiotics in Laboratory Medicine 2005, 365-440. Lippincott, Williams & Wilkins, Philadelphia. V. Lorian (Ed.).
23. Prescott J.F., Nicholson V.M. The effects of combinations of selected antibiotics on the growth of Corynebacterium equi. J. Vet. Pharmacol. Ther. 1984, 7:61-64.
24. Spivey J.M. The postantibiotic effect. Clin. Pharm. 1992, 11:865-875.
25. Sweeney C.R., Sweeney R.W., Divers T.J. Rhodococcus equi pneumonia in 48 foals: response to antimicrobial therapy. Vet. Microbiol. 1987, 14:329-336.
26. Yamori S., Ichiyama S., Shimokata K., Tsukamura M. Bacteriostatic and bactericidal activity of antituberculosis drugs against Mycobacterium tuberculosis, Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium kansasii in different growth phases. Microbiol. Immunol. 1992, 36:361-368.
27. Yamshchikov A.V., Schuetz A., Lyon G.M. Rhodococcus equi infection. Lancet Infect. Dis. 2010, 10:350-359.
28. Zhanel G.G., Craig W.A. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin. Pharmacokinet. 1994, 27:377-392.